Both in vitro and in vivo results showed that this complex nanocarrier decreased Alzheimer’s disease consequences, diminishing mitochondrial oxidative stress and inhibiting tau hyperphosphorylation and neuronal apoptosis, yielding a synergistically improved therapeutic alternative. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.